10.11.2022
SITC 37th Annual Meeting

Glycostem is going to present a poster at the SITC 37th Annual Meeting, held November 10-12, 2022,  in Boston, MA, USA.

Title: Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia

Abstract Number: 245

Presentation and Session Information*
Annual Meeting Regular Poster Abstract Presenter:    (245) Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia
    Poster Hall
    11/10/2022 - 11/11/2022, 9:00 am - 9:00 pm

Presented by: Monica Raimo

 

07.11.2022
Cell UK

Glycostem CDO Volker Huppert will be speaking at Cell Series UK conference on 7th - 8th November, 2022.

02.11.2022
Onco Cell Therapy Summit Europe

Glycostem CEO Troels Jordansen will present at the Onco Cell Therapy Summit Europe taken place on 2nd-3rd Nov 2022 in Amsterdam.

Date and time: 2nd Nov 2022 11:00 (CET)
Presentation title: Developing end-to-end, closed manufacturing of NK cell therapy from umbilical cord blood (UCB)- derived stem cells
• Set-up of production and implementing automation
• Exploration of how this process can reduce investment

20.10.2022
Innate Killer Summit Europe

Glycostem CDO Volker Huppert and CMO Kai Pinkernell are going to present at the Innate Killer Summit Europe.

20th Oct 2022 08:30 GMT+1, Volker Huppert:

Maximising Product Stability by Understanding Fundamental Elements of Stability to Advance Cryopreservation Protocols

20th Oct 2022 14:30 GMT+1 Kai Pinkernell:

Bringing Allogeneic NK cells into Clinical Trials for AML

21.09.2022
22nd Annual Biotech in Europe Forum

Glycostem to participate 22nd Annual Biotech in Europe Forum (BEF), in-person event on 21st-22nd of September 2022 at Basel, Switzerland.

01.09.2022
Advanced Therapies Europe

Glycostem CEO Troels Jordansen and CMO Kai Pinkernell to present at the Advanced Therapies Europe, on 1st Sep 2022 in the below sessions:

09:00 SPOTLIGHT ROUNDTABLES
ROUNDTABLE 6: PATIENT ENGAGEMENT DURING CLINICAL DEVELOPMENT: KEEPING THE ‘CUSTOMER’ IN MIND 
Moderator: Kai Pinkernell, Chief Medical Officer, Glycostem

13:55 – CASE STUDY: OPTIMISING FACILITY & LOCATION FOR CANCER CARE
Speaker: Troels Jordansen, CEO, Glycostem Therapeutics